Not Signed In -
Pioglitazone |
Actos |
Pioglitazone Systematic (IUPAC) name 5-((4-(2-(5-ethyl-2-pyridinyl) ethoxy)phenyl)methyl)-,(+-)- 2,4-thiazolidinedione, Identifiers CAS number 111025-46-8 ATC code A10BG03 PubChem 4829 DrugBank APRD00653 Chemical data Formula C19H20N2O3S Mol. weight 356.44 g/mol Pharmacokinetic data Bioavailability ? Protein binding > 99% Metabolism ? Half life 3-7 hours Excretion ? Therapeutic considerations Pregnancy cat. ? Legal status ...
Wikipedia - [full article]
Pioglitazone Clinical Trials
- Effect of Pioglitazone
ClinicalTrials.gov Identifier: NCT00232362 - Recruiting
Type 2 Diabetes Mellitus
- Treating Nonalcoholic Steatohepatitis with Pioglitazone
ClinicalTrials.gov Identifier: NCT00062764 - Recruiting
Hepatitis
- Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Non-Diabetic Patients with Nonalcoholic Steatohepatitis (PIVENS)
ClinicalTrials.gov Identifier: NCT00063622 - Active, not recruiting
Liver Diseases
- A Study to Evaluate SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone, or Pioglitazone HCl Alone for the Treatment of Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00395512 - Active, not recruiting
Type 2 Diabetes Mellitus
- Pioglitazone in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
ClinicalTrials.gov Identifier: NCT00099021 - Active, not recruiting
lip and oral cavity cancer; Oropharyngeal Cancer; Oral Leukoplakia
- Anti-Inflammatory Effects of Pioglitazone in Non-Diabetic Patients with Stage 4 and 5 Chronic Kidney Disease
ClinicalTrials.gov Identifier: NCT00169923 - Recruiting
Chronic Kidney Disease; Inflammation
- Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE)
ClinicalTrials.gov Identifier: NCT00225277 - Active, not recruiting
Diabetes Mellitus, Type 2; Coronary Artery Disease
- Role of Pioglitazone in Preventing Diabetes
ClinicalTrials.gov Identifier: NCT00276497 - Active, not recruiting
Diabetes
- Initial Combination With Pioglitazone Study
ClinicalTrials.gov Identifier: NCT00397631 - Recruiting
Type 2 Diabetes Mellitus
- Placebo-Controlled Study of the Combination of SYR-322 and Pioglitazone HCl in the Treatment of Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00328627 - Active, not recruiting
Type 2 Diabetes Mellitus
- Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00237237 - Active, not recruiting
Diabetes Mellitus, Type 2
- Study of SYR-322 Combined With Pioglitazone in the Treatment of Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00286494 - Active, not recruiting
Type 2 Diabetes Mellitus
- Effect of Pioglitazone on Ambulatory Blood Pressure
ClinicalTrials.gov Identifier: NCT00328393 - Recruiting
Hypertension; Diabetes Mellitus Type 2
- Pioglitazone Vs Placebo in Combination With Niacin Extended Release on Low HDL
ClinicalTrials.gov Identifier: NCT00300365 - Recruiting
Metabolic Syndrome
- Combination of Pioglitazone and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
ClinicalTrials.gov Identifier: NCT00362440 - Recruiting
HIV Lipodystrophy
- Influence of Pioglitazone for Renal Transplant Function in Diabetics
ClinicalTrials.gov Identifier: NCT00507494 - Recruiting
Diabetes Mellitus; Kidney Transplantation; Proteinuria
- Pilot Mouthwash Study of Pioglitazone and Simvastatin in Healthy Volunteers
ClinicalTrials.gov Identifier: NCT00531882 - Recruiting
Cystic Fibrosis; Anti Inflammatory Non-Steroidal; Neutrophils
- MK0431 Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov Identifier: NCT00372060 - Active, not recruiting
Type 2 Diabetes Mellitus
- Pioglitazone Protects DM Patients Against Re-Infarction (PPAR Study)
ClinicalTrials.gov Identifier: NCT00212004 - Recruiting
Diabetes Mellitus; Myocardial Infarction
- Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
ClinicalTrials.gov Identifier: NCT00231894 - Recruiting
Diabetes; Schizophrenia; Insulin Resistance; Cognitive Impairment
- "TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM
ClinicalTrials.gov Identifier: NCT00402012 - Recruiting
Diabetes Mellitus, Type 2
- Pioglitazone to Treat Fatty Liver in People With HIV Infection
ClinicalTrials.gov Identifier: NCT00441272 - Recruiting
HIV Infections; Hepatic Steatosis; Insulin Resistance
- Study In People With Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00196989 - Active, not recruiting
Type 2 Diabetes Mellitus
- Pioglitazone Treatment in Polycystic Ovary Syndrome
ClinicalTrials.gov Identifier: NCT00145340 - Active, not recruiting
Polycystic Ovary Syndrome
- Insulin Action in Individuals With Type 2 Diabetes by Natural Fatty Acids or the Medication Pioglitazone
ClinicalTrials.gov Identifier: NCT00179400 - Recruiting
Type 2 Diabetes Mellitus
- Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus
ClinicalTrials.gov Identifier: NCT00511108 - Recruiting
Diabetes Mellitus, Non-Insulin-Dependent
- Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis
ClinicalTrials.gov Identifier: NCT00570622 - Recruiting
Cirrhosis; Ascites; Portal Hypertension
- Retreatment of Chronic Hepatitis C Non-Responders With Pegylated Interferon Alpha + Ribavirin + Pioglitazone
ClinicalTrials.gov Identifier: NCT00433069 - Recruiting
Chronic Hepatitis C
- Pioglitazone in Hepatitis C
ClinicalTrials.gov Identifier: NCT00189163 - Recruiting
Chronic Hepatitis C
- Pioglitazone on Cardiac Function and Large Arteries (PICCOLA Study)
ClinicalTrials.gov Identifier: NCT00485056 - Not yet recruiting
Diabetes
- A Study to Evaluate SYR-322 Plus Pioglitazone HCl (ACTOS®) for the Treatment of Subjects With Inadequately Controlled Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00432276 - Recruiting
Type 2 Diabetes Mellitus
- Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients
ClinicalTrials.gov Identifier: NCT00399204 - Recruiting
Type 2 Diabetes
- Effects of Insulin Sensitizers in Subjects with Impaired Glucose Tolerance
ClinicalTrials.gov Identifier: NCT00108615 - Recruiting
Glucose Metabolism Disorders
- Investigation of Vascular Relaxing Effects of Candesartan and Pioglitazone.
ClinicalTrials.gov Identifier: NCT00154037 - Completed
Healthy subjects
- Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis
ClinicalTrials.gov Identifier: NCT00395941 - Not yet recruiting
Psoriasis
- The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers at Eight Months After Zotarolimus-Eluting Stent Implantation in Diabetic Patients
ClinicalTrials.gov Identifier: NCT00494559 - Not yet recruiting
Diabetes Mellitus; Coronary Artery Stenosis
- Insulin Resistance Intervention After Stroke (IRIS) Trial
ClinicalTrials.gov Identifier: NCT00091949 - Recruiting
Stroke; Myocardial Infarction; Diabetes
- Role of Pioglitazone in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
ClinicalTrials.gov Identifier: NCT00227110 - Recruiting
Non Alcoholic Steatohepatitis (NASH)
- Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus
ClinicalTrials.gov Identifier: NCT00545857 - Recruiting
Type 1 Diabetes Mellitus
- Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in the Metabolic Syndrome
ClinicalTrials.gov Identifier: NCT00408850 - Not yet recruiting
Metabolic Syndrome
- PIoglitazone for PrEvention of Restenosis in Diabetic Patients
ClinicalTrials.gov Identifier: NCT00376870 - Not yet recruiting
Coronary Atherosclerosis; Coronary Restenosis; Diabetes
- A Study of PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.
ClinicalTrials.gov Identifier: NCT00545233 - Not yet recruiting
Hepatitis C, Chronic
- Treatment of Coronary Atherosclerosis By Insulin Sensitizers In Insulin-Resistant Patients
ClinicalTrials.gov Identifier: NCT00155350 - Recruiting
Coronary Atherosclerosis; Coronary calcification; Plaque vulnerability; Inflammation; Coronary Heart Disease
- GALLANT 6 Tesaglitazar Vs. Pioglitazone
ClinicalTrials.gov Identifier: NCT00214565 - Completed
Diabetes Mellitus, Type 2
- Liver Safety of Pioglitazone
ClinicalTrials.gov Identifier: NCT00494312 - Completed
Diabetes Mellitus, Type 2
- Abdominal Adipose Tissue Distribution in Type 2 Diabetic Patients Treated During 6 Months with Pioglitazone or Insulin
ClinicalTrials.gov Identifier: NCT00159211 - Terminated
Type 2 Diabetes
- Pioglitazone and Losartan Provides Additional Renoprotection
ClinicalTrials.gov Identifier: NCT00364988 - Completed
Type 2 Diabetes; Diabetic Nephropathy
- Effects of Pioglitazone in Congenital Adrenal Hyperplasia
ClinicalTrials.gov Identifier: NCT00151710 - Completed
Congenital Adrenal Hyperplasia
- Safety and Efficacy of Pioglitazone as an Anti-Inflammatory for the Treatment of CF Lung Disease
ClinicalTrials.gov Identifier: NCT00322868 - Completed
Cystic Fibrosis
- Comparison Between Pioglitazone and SES With type2 DM
ClinicalTrials.gov Identifier: NCT00482183 - Completed
Coronary Artery Disease; Type 2 Diabetes Mellitus
- Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients
ClinicalTrials.gov Identifier: NCT00148850 - Terminated
HIV-Associated Lipodystrophy Syndrome; HIV Infections
- Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults
ClinicalTrials.gov Identifier: NCT00352287 - Completed
Obesity; Metabolic Syndrome; Impaired Glucose Tolerance
- Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as Add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin
ClinicalTrials.gov Identifier: NCT00384215 - Completed
Diabetes Mellitus, Type 2
- A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics
ClinicalTrials.gov Identifier: NCT00240370 - Completed
Type 2 Diabetes
- BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-
ClinicalTrials.gov Identifier: NCT00297063 - Completed
Non-Insulin-Dependent Diabetes Mellitus
- A Study to Assess the Changes in HbA1C and Lipids in 6 Months of Treatment With Pioglitazone, and to Assess Genetic Polymorphisms in PPAR-Gamma
ClinicalTrials.gov Identifier: NCT00449553 - Completed
Type 2 Diabetes
- Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone
ClinicalTrials.gov Identifier: NCT00402909 - Completed
Type 2 Diabetes
- Metabolic Effects of Pioglitazone in Type II Diabetic Patients Previously Treated With Insulin
ClinicalTrials.gov Identifier: NCT00576784 - Completed
Type 2 Diabetes Mellitus; Insulin Resistance
- The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome
ClinicalTrials.gov Identifier: NCT00314561 - Completed
Metabolic Syndrome
- Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00419484 - Completed
Type 2 Diabetes; Hypertension; Dyslipidemia; Diabetic Nephropathy
- A Study of Pioglitazone HCl Versus Glimepiride in Subjects With Type 2 Diabetes Measuring the Progression of Atherosclerosis (CHICAGO)
ClinicalTrials.gov Identifier: NCT00225264 - Completed
Diabetes Mellitus, Type 2; Coronary Artery Disease
- Effect of Pioglitazone Therapy for Type 2 Diabetes on Vision
ClinicalTrials.gov Identifier: NCT00548158 - Completed
Type 2 Diabetes
- Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
ClinicalTrials.gov Identifier: NCT00189774 - Completed
Type 2 Diabetes Mellitus; Diabetes Mellitus, Type II
- The Effect of Pioglitazone on Macrovascular Outcome (Death, Heart Attack, Acute Coronary Syndrome, Heart Bypass Surgery, Stroke, Leg Bypass Surgery or Amputation) in Patients With Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00174993 - Completed
Type 2 Diabetes
- Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease
ClinicalTrials.gov Identifier: NCT00479986 - Completed
Type 2 Diabetes Mellitus; Cardiovascular Disease
- A Comparison of Pioglitazone HCl and Glyburide in the Treatment of Patients With Type 2 Diabetes Mellitus and Mild Cardiac Disease
ClinicalTrials.gov Identifier: NCT00521742 - Completed
Diabetes Mellitus, Type 2; Cardiac Disease
- Study of Muraglitazar versus Pioglitazone in Type 2 Diabetics
ClinicalTrials.gov Identifier: NCT00106808 - Completed
Type 2 Diabetes Mellitus
- Pioglitazone Versus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia
ClinicalTrials.gov Identifier: NCT00331487 - Completed
Type 2 Diabetes Mellitus; Dyslipidemia
- A clinical trial to prevent the complications of insulin resistance (including type-2 diabetes)
ClinicalTrials.gov Identifier: NCT00015626 - Completed
Insulin Resistance; Diabetes Mellitus
- A Study to Compare Pioglitazone HCl and Glyburide for the Treatment of Subjects With Type 2 Diabetes Mellitus and Mild to Moderate Congestive Heart Failure
ClinicalTrials.gov Identifier: NCT00521820 - Completed
Type 2 Diabetes Mellitus; Congestive Heart Failure
- Pioglitazone Add-on Study in Patients with Type 2 Diabetes Mellitus
ClinicalTrials.gov Identifier: NCT00086502 - Completed
Diabetes Mellitus, Type 2
- Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00143520 - Completed
Type 2 Diabetes
- Treatment of Nonalcoholic Steatohepatitis with Pioglitazone
ClinicalTrials.gov Identifier: NCT00013598 - Completed
Fatty Liver; Nonalcoholic Steatohepatitis
- NovoLog Mix 70/30 with Anti-Diabetic Drugs compared to the Anti-Diabetic Drugs Alone in Patients with Type 2 Diabetes
ClinicalTrials.gov Identifier: NCT00097279 - Completed
Diabetes Mellitus, Type II
Resources
- Actos (Drug Digest)
- Actos Consumer Information (U.S. Food and Drug Administration)
email this page
print this page
bookmark this page
feedback on this page